This patent covers neural stem cells of a specific phenotype and their use for delivery of gene products into an area of need.
The stem cells that generate T cells originate in the bone marrow and differentiate in the thymus. This patent teaches that T cell precursors can be expanded in high oxygen conditions in a thymic-like microenvironment. This patent is very interesting not only from the point of view of generating T cells for immune stimulation, but also because theoretically it can be applied to the generation...
Anyone performing autologous hematopoietic stem cell transplants should watch out for this patent !! This patent teaches essentially autologous transplantation with ex vivo expansion of stem cells. Numerous companies and scientists are doing or have done clinical investigations which potentially infringe on this patent.
This patent provide tissue culture reagents for the expansion of hematopoietic stem cells.
This patent uses mast cell growth factor as an additive to tissue culture media in order to generate a liquid composition that is useful for expansion of hematopoietic stem cells. The ability of this media to expand other types of stem cells should be assessed.
This patent covers methods of expanding stem cells derived from the hair follicle. One of the methods of expanding hair follicle stem cells is through growing then on 3T3 fibroblasts.
Hair stem cells are somewhat similar to mesenchymal stem cells and may be useful for a wide variety of applications in addition to
This patent provides certain morphogen proteins that are capable of regenerating neural stem cells, as well as protecting neurons from apoptosis or other types of cell death. The claims cover specific polypeptides for neurite extension, as well as for repairing the gap between neurons.
This patent teaches the production of a chemical composition useful for growing hair in bald people. The composition is made from media conditioned by growing epithelial cells. The composition is mitogenic to dermal papilla cells and 3T3 fibroblasts but not to epidermal cells. The molecular weight of the active ingredient is > 3 kDa.
This patent teaches that uteroferrin (placental Type V acid phosphatase) is a stimulator of hematopoietic stem cells. Uteroferrin is made during pregnancy and is associated with iron transport. The use of uteroferrin for hematopoiesis may be a potent new way of approaching the problem of neutropenia.
This patent teaches that members of the FGF family are useful for expansion of hematopoietic stem cells. This is interesting since FGF-2 was actually used in the clinic for treatment of stroke. Although results were impressive in small subsets of patients, the adverse effects of systemic administration of this protein stopped its clinical...